Related Experiment Video
Updated: Dec 31, 2025
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy
Ryan D Salinas1, Joseph S Durgin1, Donald M O'Rourke2,3
1Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Abstract:
Despite the established efficacy of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies, translating CAR T therapy to solid tumors has remained investigational. Glioblastoma, the most aggressive and lethal form of primary brain tumor, has recently been among the malignancies being trialed clinically with CAR T cells. Glioblastoma in particular holds several unique features that have hindered clinical translation, including its vast intertumoral and intratumoral heterogeneity, associated immunosuppressive environment, and lack of clear experimental models to predict response and analyze resistant phenotypes. Here, we review the history of CAR T therapy development, its current progress in treating glioblastoma, as well as the current challenges and future directions in establishing CAR T therapy as a viable alternative to the current standard of care. Tremendous efforts are currently ongoing to identify novel CAR targets and target combinations for glioblastoma, to modify T cells to enhance their efficacy and to enable them to resist tumor-mediated immunosuppression, and to utilize adjunct therapies such as lymphodepletion, checkpoint inhibition, and bi-specific engagers to improve CAR T persistence. Furthermore, new preclinical models of CAR T therapy are being developed that better reflect the clinical features seen in human trials. Current clinical trials that rapidly incorporate key preclinical findings to patient translation are emerging.
Insights
Chimeric antigen receptor (CAR) T-cell therapy shows promise for glioblastoma, a deadly brain cancer. Overcoming tumor heterogeneity and immunosuppression are key challenges for successful CAR T-cell therapy in solid tumors.
Area of Science:
- Oncology
- Immunotherapy
- Neuro-oncology
Background:
- Chimeric antigen receptor (CAR) T-cell therapy is effective in blood cancers but faces challenges in solid tumors.
- Glioblastoma (GBM) is an aggressive brain tumor with unique features hindering CAR T-cell therapy translation.
- CAR T-cell therapy for glioblastoma is investigational, requiring novel strategies to overcome treatment resistance.
Purpose of the Study:
- To review the history and current progress of CAR T-cell therapy for glioblastoma.
- To discuss the challenges and future directions for CAR T-cell therapy in treating glioblastoma.
- To highlight advancements in preclinical models and clinical trial designs for glioblastoma CAR T-cell therapy.
Main Methods:
- Review of existing literature on CAR T-cell therapy in glioblastoma.
- Analysis of challenges including tumor heterogeneity and immunosuppression.
- Exploration of novel CAR targets, T-cell modifications, and adjunct therapies.
Main Results:
- CAR T-cell therapy for glioblastoma faces significant hurdles due to tumor biology.
- Ongoing research focuses on identifying new targets, enhancing T-cell function, and overcoming immunosuppression.
- Development of improved preclinical models and adaptive clinical trial designs is crucial.
Conclusions:
- CAR T-cell therapy holds potential for glioblastoma but requires overcoming substantial biological barriers.
- Future strategies involve combination therapies, T-cell engineering, and better predictive models.
- Translational research is rapidly advancing to improve CAR T-cell therapy efficacy in glioblastoma patients.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...